Post-traumatic stress disorder

• Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced that it will ring the Nasdaq closing bell on Monday, July 24, 2023.
• “We are honored to ring the closing bell on July 24th and recognize the hard work and outstanding contributions from our entire team.
• We have made tremendous progress in moving our product candidates forward and expect to be in human clinical trials in 2024,” stated Anthony P. Mack , Chairman and CEO of Virpax.
• The Closing Bell ceremony will be broadcast live from the Nasdaq MarketSite Tower in New York City.

• At the Mosaic Refugee Health Clinic in Calgary, we tallied the physical damage, mental trauma and how families were ripped apart.
• They insisted that the atrocities of genocide should never be forgotten and the culprits face justice.
• These are the narratives shared by Yazidi refugees who were resettled through Canada’s Survivors of Daesh Program in Calgary and three other major Canadian cities between 2017 and 2019.
• Although our clinic is one of the largest and longest-running specialized refugee health clinics in Canada, the rapid resettlement of 242 Yazidi refugees nearly broke us.

Documenting genocide

• “When genocide is committed, it must be seen.” – Yazidi refugee, Nobel Peace Prize laureate and human rights activist Nadia Murad
  “When genocide is committed, it must be seen.” – Yazidi refugee, Nobel Peace Prize laureate and human rights activist Nadia Murad The resulting research is a community- and clinician-engaged cross-sectional study, which was recently published in the JAMA Network Open.
• We offer it as a testament to the world, documenting the depths of human depravity and its darkest impulses.
• The horrors of genocide defy comprehension, but in our ongoing struggle for human rights amid increasing global displacement, we must confront them.
• Yazidi refugees are calling on the world to open its eyes to genocide, while indiscriminate killings and violence against women and children are, yet again, being used as weapons of war in Afghanistan, Ukraine and Sudan.

Refugee health policy summit

• In the final act of healing, Refugee Health YYC will host Yazidi refugee, Nobel Peace Prize laureate and human rights activist Nadia Murad in Calgary, a refugee health policy summit, and for the first time, the North American Refugee Health Conference July 21-23.
• These events will bring together health-care providers, researchers, policymakers and refugee leaders to learn from one another and develop new models to improve health care and well-being for the 108.3 million people forcibly displaced around the world.
• Gabriel E. Fabreau MD, MPH, FRCPC receives research grants from the Canadian Institutes of Health Research (CIHR), Alberta Innovates, MSI Foundation, and the University of Calgary.

• The havoc wreaked by the COVID-19 pandemic compelled leading companies to adopt state-of-the-art technologies, such as metaverse, augmented reality (AR) and virtual reality.
• Immersive technologies have forayed into a host of industries, such as education, healthcare, entertainment, manufacturing, logistics and sports.
• The technology has come to the fore (not an exhaustive list) to boost surgery, help manage post-traumatic stress disorder and offer physical therapy.
• Immersive media technologies in the Asia Pacific have gained ground against the backdrop of flourishing gaming, entertainment and media industries.

• In particular, Professor Gertsch presented key scientific results that led to the identification and characterization of the biological machinery responsible for endocannabinoid cell reuptake.
• Synendos was founded to exploit the therapeutic potential of this novel mode of action and is developing SERIs as first-in-class inhibitors that modulate a newly identified drug target in the ECS.
• The pioneering research performed by Professor Gertsch's team forms the basis of Synendos' approach and represents the most advanced therapeutic approach using this mode of action with clinical studies anticipated in the near future.
• Dr Andrea Chicca, Co-Founder and CEO of Synendos, commented: "Professor Jürg Gertsch's groundbreaking findings, disclosed yesterday for the first time, are the culmination of more than a decade of research into an entirely new mechanism for the treatment of challenging neuropsychiatric conditions.